Navigation Links
Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in,Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results of a preclinical study with ACE-031 that demonstrated the ability of the compound to increase muscle mass and strength in normal mice and in murine models of muscular dystrophy. ACE-031 inhibits negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and cancer-related muscle loss. The data was presented on Sunday, May 13 at the Gordon Research Conference on Myogenesis in Lucca, Italy. ³

Acceleron is encouraged by the significant outcomes and positive data generated by ACE-031 spanning numerous preclinical models of muscle loss², said Jas Seehra, Ph.D., Chief Scientific Officer of Acceleron. ³ACE-031 and related Acceleron compounds consistently demonstrate substantial increases in skeletal muscle mass and strength.² ACE-031, a protein therapeutic based on the activin receptor type IIB (ActRIIB), is the first of several compounds Acceleron is developing for the treatment of diseases involving the loss of muscle mass, strength and function. ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength. Over-expression of myostatin has been shown to cause a loss in muscle mass and strength, and inhibition of myostatin results in the selective increase in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia).

ACE-031 offers the potential for an entirely new type of therapy for the treatment of various muscle wasting conditions. ³The clinical potential of ACE-031 to selectively increase skeletal muscle will offer
'"/>




Page: 1 2 3

Related medicine technology :

1. Acceleron Pharmas ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
2. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
3. Rapid HIV Testing Increases Possibility of Treatment
4. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
5. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
6. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
7. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and related ... evening dresses . All the company’s old and new ... is up to 66 percent off. , SweetDressy.com ... field. Its dress specialists are striving to make more ... the world. All the company’s items are unique, graceful ...
(Date:10/19/2014)... causes inflammation in the spinal joints and was ... Egyptian royal families. Now a new study published ... of the American College of Rheumatology (ACR), refutes ... called diffuse idiopathic skeletal hyperostosis (DISH) in royal ... Dynasties. , Ankylosing spondylitis is a member ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... The National Alliance on Mental Illness (NAMI) reminds ... Health Awareness Month, a time for public education about serious ... 2008, the U.S. House of Representatives designated July as Bebe ... of the leading African American novelist and journalist, who also ...
... Va., July 1 Christian Children,s Fund, one ... now ChildFund International. The new name takes effect today. ... the organization,s new strategy to meet the needs of children ... and helps 15.2 million children and family members in 31 ...
... 21 criminal convictions secured , , INDIANAPOLIS, July 1 ... its Fraud and Abuse department, working with its ... 2008 as a result of its anti-fraud efforts. These efforts ... agencies. , , This announcement comes the day ...
... a micro-thin shield against acid attack -- , ... L. Moore, MD, wants women to know that their dental ... Crest and Oral-B Pro-Health products because they offer preventive solutions ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090701/NY38331 ...
... Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) ... U.S. / Canada Dial-in Number: 866.272.9941, ... Code: 45596036, Replay Dial-in Number: 888.286.8010, ...
... Kids watching food commercials consumed 45 percent more snacks, study ... ads on TV leads to a boost in snacking among ... researchers say. , Yale University researchers conducted a series of ... One test found that children aged 7 to 11 who ...
Cached Medicine News:Health News:NAMI Observes Minority Mental Health Awareness Month 2Health News:Christian Children's Fund Name Change to ChildFund International Official 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 3Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 2Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:TV Ads Trigger Mindless Eating 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: